Cold Genesys, Inc. (ColdGenesys)

Oncology Corporate Profile

HQ Location

1303 Avocado Ave. Suite 255
Newport Beach, CA 92660

Company Description

Cold Genesys, Inc. is a privately-held, clinical-stage oncolytic viral immunotherapy company with its lead product CG0070 now in an integrated Phase II/III clinical trial for bladder cancer. CG0070 is a conditionally replication-competent adenovirus, containing an E2F promoter in the viral E1A region that drives the expression of GM-CSF. CGI also has developed n-dodecyl-D-maltoside to specifically enhance viral transduction in cancer cells. CG0070 was previously tested in a Phase I/II trial of 35 patients with non-muscle invasive bladder cancer in 2008.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CG0070oncolytic virusBladder cancerIII
CG0070 (+ immune checkpoint moduator)oncolytic virusBladder cancerI
CG0070 (+ immune checkpoint moduator)oncolytic virusVarious cancer typesI
CG0161anti-CTLA-4 antibodyVarious cancer typesPreclinical

View additional information on product candidates here »


Recent News Headlines

There are no news items to display